A Novel Recombinant Soluble Human Thrombomodulin, ART‐123, Activates the Protein C Pathway in Healthy Male Volunteers

Publisher Website
Google Scholar
Abstract
The effect of a novel recombinant soluble human thrombomodulin, ART‐123, on protein C activation was investigated by measuring plasma prothrombinase activity in four healthy male volunteers. ART‐123 at a dose of 0.3 mg was administered as a bolus intravenous injection for 1 minute. Plasma ART‐123 concentration and prothrombinase activity were determined before and immediately, 24, and 48 hours after injection, and thromboelastography was recorded before and immediately and 24 hours after injection. The mean elimination half‐life was 19.82 ± 2.10 hours. Compared with pretreatment levels, ART‐123 reduced prothrombinase activity by 44.2 ± 11.7%, 52.1 ± 10.8%, and 61.0 ± 14.7%, respectively, immediately, 24, and 48 hours after injection, suggesting that ART‐123 activated the protein C pathway. ART‐123 did not affect thromboelastography values. There were no abnormal findings for objective signs or laboratory tests, including blood pressure, heart rate, electrocardiogram, body temperature, hematology, coagulation and hemostatic parameters, blood chemistry, and urinalysis. Based on these observations, ART‐123 at a dose of 0.3 mg can activate the protein C pathway in healthy volunteers.